Evidence map›Paper›PMID 40457441›Full record

ArticleGenome medicine2025

Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy.

Xiaohong Liu, Yue Sun, Boxu Lin, Hao Xiong, Xinyue Lu, Binghe Tan, Chenglin Zhang, Mingyao Liu, Juliang Qin, Na Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaohong Liu *Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Yue Sun *Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Boxu Lin *Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Hao XiongShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Xinyue LuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Binghe TanBRL Medicine Inc., Shanghai, 201109, China.
Chenglin ZhangShanghai Changzheng Hospital, Shanghai, 200003, China.
Mingyao LiuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
Juliang QinShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China. jlqin@bio.ecnu.edu.cn.
Na ZhangShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China. nzhang@brlmed.com.
Bing DuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, 200241, China. bdu@bio.ecnu.edu.cn.

Funding

National Key R&D Program of China 2023YFC3402000National Natural Science Foundation of China 82173099National Natural Science Foundation of China 82430092Program of Shanghai Academic/Technology Research Leader 23XD1430600Science and Technology Commission of Shanghai Municipality 23141901800Science and Technology Commission of Shanghai Municipality 23141903300Science and Technology Commission of Shanghai Municipality 24J22801200Shanghai Municipal Health Commission 2024CXJQ01
6 · The paper itself

Abstract

backgroundChimeric antigen receptor T (CAR-T) cell therapy has shown remarkable success in treating hematologic malignancies. However, its efficacy against solid tumors remains limited. One of the major challenges is the lack of specific tumor antigens. Therefore, the exploration and rational selection of novel tumor targets is urgently needed. In this study, we investigate the therapeutic potential of targeting CD155 in cancer by CAR-T cells.

methodsThe expression of CD155 was analyzed across various cancer types using data from The Cancer Genome Atlas (TCGA) and validated by tissue microarray analysis. The impact of CD155 on T cell mediated cytotoxicity was analyzed using CD155 over-expression or knockout tumor cells. Subsequently, second-generation CAR-T cells were constructed using either the extracellular domain (ECD) of TIGIT or an anti-CD155 scFv to evaluate their anti-tumor efficacy both in vitro and in vivo.

resultsWe demonstrated that CD155 is specifically overexpressed across various cancer types and that its high expression is strongly associated with poor prognosis, as revealed by data from TCGA. Consistently, CD155 is significantly upregulated in clinical tumor tissues and in numerous cancer cell lines, while it is rarely expressed in normal tissues. Furthermore, CD155 expression is also significantly increased in granulocytes derived from cancer patients compared to those from healthy donors. Functionally, high CD155 expression significantly inhibits the release of cytotoxic factors from T cells, thereby functioning as an immune checkpoint that mediates tumor immune evasion. After comparison, the scFv based anti-CD155 CAR-T cells demonstrated stronger anti-tumor activity than ECD of TIGIT based CAR-T cells. Moreover, the scFv based CAR-T cells exhibited effective anti-tumor activity against multiple CD155

conclusionsOur study demonstrates that CD155 is selectively expressed in cancer cells while being rarely detected in normal tissues, and may serve as a promising pan-cancer target for CAR-T therapy. Targeting CD155 with CAR-T cells provides an effective approach to treating both solid and hematologic malignancies.

Indexed as

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenReceptors, VirusAnimalsCell Line, TumorHumansMiceT-LymphocytesXenograft Model Antitumor Assayspoliovirus receptorReceptors, Chimeric AntigenReceptors, VirusCAR-TCD155/PVRPan-cancerTargetsTIGIT

Identifiers

PMID40457441
PMCPMC12128359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.